Assessment of glomerular function by monitoring for proteinuria, hypertension, and reduced renal function could be particularly important for patients with preexisting renal disease or a CFH genetic variant receiving anti-VEGF therapy. This evidence concerns the gene VEGFA and kidney disorder.